Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 13/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.33 |
| ▸ | PAK4 | O96013 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13927717 | 1.00 | CHEK1 (0.37) | CHEK1KDRALDH1A1MEN1KMT2A | |
| SCHEMBL5029967 | 0.90 | PAK4 (0.33) | CHEK1KDRFGFR1AURKAAURKB | |
| SCHEMBL13927723 | 0.90 | PAK4 (0.33) | CHEK1KDRFGFR1AURKAAURKB | |
| SCHEMBL5031154 | 0.89 | TRPV3 (0.41) | CHEK1KMT2AAURKAAURKBROCK2 | |
| SCHEMBL13927706 | 0.89 | ROCK2 (0.38) | CHEK1KDRFGFR1AURKAAURKB | |
| SCHEMBL5098700 | 0.89 | ROCK2 (0.38) | CHEK1KDRFGFR1AURKAAURKB | |
| SCHEMBL5030047 | 0.88 | CHEK1 (0.37) | CHEK1KDRALDH1A1MEN1KMT2A | |
| SCHEMBL13927719 | 0.87 | CHEK1 (0.38) | CHEK1KDRALDH1A1MEN1KMT2A | |
| SCHEMBL5031209 | 0.87 | CHEK1 (0.38) | CHEK1KDRALDH1A1MEN1KMT2A | |
| SCHEMBL13927740 | 0.85 | CYP1A1 (0.39) | MEN1KMT2AROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | CHEK1 657/4885KDR 1044/4885ALDH1A1 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.